Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Retained Earnings (2016 - 2025)

Avalo Therapeutics' Retained Earnings history spans 12 years, with the latest figure at -$448.5 million for Q4 2025.

  • For Q4 2025, Retained Earnings changed N/A year-over-year to -$448.5 million; the TTM value through Dec 2025 reached -$448.5 million, changed N/A, while the annual FY2025 figure was -$448.5 million, N/A changed from the prior year.
  • Retained Earnings reached -$448.5 million in Q4 2025 per AVTX's latest filing, down from -$434.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$208.5 million in Q1 2021 to a low of -$456.4 million in Q1 2024.
  • Average Retained Earnings over 5 years is -$328.2 million, with a median of -$321.7 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: plummeted 53.96% in 2021, then increased 16.0% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$262.2 million in 2021, then decreased by 15.89% to -$303.8 million in 2022, then decreased by 10.31% to -$335.1 million in 2023, then grew by 0.06% to -$334.9 million in 2024, then crashed by 33.92% to -$448.5 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Retained Earnings are -$448.5 million (Q4 2025), -$434.8 million (Q3 2025), and -$404.2 million (Q2 2025).